Analyze Historical and Forecast Ethical Sales Performance of Pharmaceutical Group Altana.

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c43858) has announced the addition of the new report from Datamonitor entitled "Altana: PharmaVitae Profile" to their offering.

This analysis examines the historical and forecast performance for Altana in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to order your copy:

-- Benchmark Altanas performance against key rivals in the ethical pharmaceutical sector

-- See how Altanas sales growth will slump following the 2009 patent expiry of Pantazol, which dominated the company's 2005 sales

-- Analyze the value of Altana Pharma's ethical offerings, present and future, in view of Nycomeds recent $5.7bn acquisition of the business unit

Key Topics Covered Include:

-- Therapeutic strategy

-- Launch and expiry outlook

-- Corporate history

-- Background

-- Key corporate developments

-- European healthcare reforms

-- Historical performance

-- Revenue and growth rate analysis, 2002-05

-- Revenue and growth rate vs. peer set

-- Product analysis, 2002-05

-- Forecast performance

-- Key products and competitors

-- Competitive landscape

For more information visit http://www.researchandmarkets.com/reports/c43858

Source: Datamonitor